CSL delivered a messy result. Although they did say they are on track to achieve FY guidance, gross margins and 1H adjusted ...

A weak vaccine result dragged on CSL's H1 result but analysts focus on an improving plasma product margin and solid growth forecasts in maintaining positive views ...

In a report released today, Steven Wheen from Jarden maintained a Buy rating on CSL (CMXHF – Research Report), with a price target of A$314.37.

But which of these two stocks is more attractive to value investors? We'll need to take a closer look to find out. We have found that the best way to discover great value opportunities is to pair a ...

In a report released yesterday, David Stanton from Jefferies maintained a Buy rating on CSL (CMXHF – Research Report), with a price target of ...

“CSL delivered a solid result for the first half of the 2025 financial year led by CSL Behring. Strong demand for many of our market-leading therapies has translated into sales growth, particularly in ...

The ASX opened lower before finding some momentum with CBA rebounding after a dip following release of its half-yearly ...

CSL Ltd (ASX: CSL) shares dropped to a 52-week low on Tuesday. Do brokers believe that this is a buying opportunity? Let's ...

CEO Paul McKenzie announced a reaffirmation of guidance for fiscal 2025, targeting NPATA growth of 10% to 13%. He highlighted strong results from CSL Behring and growth in CSL Vifor, while ...

CSL’s balance sheet is in sound condition. Financial risk is low given low revenue cyclicality and product demand is being largely driven by chronic indications. We forecast CSL’s net debt to EBITDA ...

Csl Ltd ( ($CSLLY) ) has released its Q2 earnings. Here is a breakdown of the information Csl Ltd presented to its investors.

There were positives and negatives in the company's first half performance. The post CSL shares push higher despite 'mixed ...